CS and cholangiocarcinoma: Analyses using the more recent and comprehensive data from the Cancer Genome Atlas Program (https://www.cancer.gov/tcga, accessed on 7 November 2025) revealed that CS expression is altered in certain cancers, including CHOL (cholangiocarcinoma) and LIHC (liver hepatocellular carcinoma) (Figure S4, [29]).